Asenapine Tablet
Product Images NDC 62332-198

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Asenapine (NDC 62332-198). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Asenapine 10 mg

The packaging label for Asenapine Sublingual Tablets, 10 mg strength, manufactured by Alembic Pharmaceuticals Inc. The label displays dosage form sublingual tablets, includes a barcode, and shows instructions for use with illustrations on administering the sublingual tablet. The package contains 60 tablets in 6 blister cards with 10 tablets each. The label also includes important usage information and warnings.*

FDA Label Image

Asenapine 25 mg

Packaging label for Asenapine Sublingual Tablets 2.5 mg by Alembic Pharmaceuticals Inc. The label includes usage instructions, warnings, and dosage information. The packaging shows a carton layout for 60 tablets, arranged in 6 blister cards of 10 tablets each, designed for sublingual administration.*

FDA Label Image

Asenapine 5 mg

Packaging label for Asenapine Sublingual Tablets 5 mg by Alembic Pharmaceuticals Inc. The label includes dosage form (tablets), strength (5 mg), sublingual route, manufacturer, barcodes, patient instructions for use, warnings, and package description of 60 tablets in 4 blister cards of 15 tablets each. The label is shown as a flat carton dieline.*

FDA Label Image

Asenapine Figure1

A forest plot chart showing fold change and 90% confidence intervals in pharmacokinetic parameters (Cmax and AUC) of asenapine when co-administered with various CYP inhibitors, including Fluvoxamine, Imipramine, Paroxetine, Cimetidine, Carbamazepine, and Valproate. The horizontal axis shows change relative to reference from 0.5 to 2, with most values near 1.0.*

FDA Label Image

Asenapine Figure2

A forest plot showing fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of substrates/inhibitors of CYP2D6, CYP1A2/2C19/3A4, and CYP2C19/2D6 enzymes. The chart compares these changes relative to a reference in the presence of asenapine; substances include paroxetine, imipramine, and desipramine with notes on asenapine's interaction effects on CYP2D6.*

FDA Label Image

Asenapine Figure3

A figure titled 'Effect of Intrinsic Factors on Asenapine Pharmacokinetics' presenting a forest plot. It compares fold changes with 90% confidence intervals for Cmax and AUC values in populations including mild, moderate, and severe renal and hepatic impairment, smokers, and Japanese individuals relative to reference groups. The x-axis shows change relative to reference from 0 to 10.*

FDA Label Image

Asenapine Figuree

An instructional illustration showing a crossed-out fork and knife beside a glass of water and a box labeled "10 minutes," indicating no food or drink intake for 10 minutes, likely related to sublingual tablet administration.*

FDA Label Image

Figure A (Asenapine Figurea)

An instructional illustration showing hands interacting with a medication package. Labels on the image identify components including the Tablet Pack, Case, and Thumb Button, demonstrating how to open or use the medication packaging mechanism.*

FDA Label Image

Step 2 (Asenapine Figureb)

An instructional illustration showing a close-up of a hand holding a tablet above a container or blister pack, demonstrating the removal or handling of a sublingual tablet, likely for the medication Asenapine.*

FDA Label Image

Step 3 (Asenapine Figurec)

An instructional illustration showing two hands opening a medication blister pack to remove a single tablet. The image depicts the thumb pushing the tablet through the foil backing while the other hand holds the pack steady.*

FDA Label Image

Asenapine Figured

An illustration showing a person placing a sublingual tablet under the tongue using their hand, demonstrating the correct method for sublingual administration.*

FDA Label Image

Figure F (Asenapine Figuref)

Illustration showing hands opening a blister pack of Asenapine sublingual tablets. The image includes instructions to not cut or pull the blister card and warnings to remove the card from the outer carton before use.*

FDA Label Image

Structure (Asenapine Structure)

Chemical structure diagram showing the molecular structure of Asenapine and an associated acetic acid molecule, illustrating the active ingredient's chemical composition in the product. The structure includes chlorine, oxygen, nitrogen, and carbon atoms arranged in rings and chains.*

FDA Label Image

Asenapine Tabletpack

An instructional diagram illustrating a tablet pack case with a thumb button. The diagram shows how to operate the case to access the tablet pack, with accompanying steps for proper use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.